Iohexol

• DETECTION RATE AND CLASSIFICATION OF BREAST LESIONS WITH DIGITAL MAMMOGRAPHY WITH CONTRAST MEDIUM (CEDM) ALONE AND IN COMBINATION WITH TOMOS… Pending
  2024-519017-62-00 Phase II 1 country IRCCS Istituto Nazionale Tumori Fondazione Pascale
• Contrast Strategy In Fenestrated EndoVascular Aneurysm Repair Randomized Control Trial Pending
  2025-521795-58-00 Phase III/IV 1 country Region Skane
• morPHinE clearance and glomerular filtration in the Drepanocytic in crisis in REAnimation. Recruiting
  2024-511985-34-00 Phase IV 1 country Centre Hospitalier Regional Universitaire De Tours
• Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) Recruiting
  2025-523743-35-00 Phase II 1 country Universitair Medisch Centrum Groningen
• Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm… Recruiting
  2025-523306-33-00 Phase II 1 country Istituto Di Ricerche Farmacologiche Mario Negri
• method VALIDation and evaluation of non-radioactive methods to measure Glomerular Filtration Rate Recruiting
  2023-509156-34-02 Phase IV 1 country Universitair Medisch Centrum Groningen
• INtravenous Contrast computed tomography versus native computed tomography in patients with acute Abdomen and impaired Renal functiOn (INCAR… Recruiting
  2024-512084-31-00 Phase IV 2 countries University Of Helsinki
• A contrast medium sparing strategy using automated Carbon Dioxide Injection during PERIpheral vascular interventions for PREVENTion of Major… Recruiting
  2024-512876-37-00 Phase III 2 countries Universitaet Leipzig
• Prospective, multicenter, randomized, open-label, parallel-group controlled phase 3 study of tacrolimus minimization in kidney transplant re… Recruiting
  2022-502624-44-00 Phase III 3 countries Centre Hospitalier Universitaire De Nantes
• Double-blind Placebo-Controlled Randomized Clinical Trial of Mineralocorticoid Receptor Blockade With Eplerenone After Renal Transplantation… Recruiting
  2024-517408-12-00 Phase III 1 country CHRU De Nancy
• A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes (TR… Ended
  2023-506082-60-00 Phase II 3 countries Eli Lilly & Co.
• Vonafexor in Impaired Renal Function and Suspected MASH Ended
  2023-509192-16-00 Phase II 1 country ENYO Pharma
• A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without T… Ended
  2023-504583-42-00 Phase II 2 countries Eli Lilly & Co.
• Finerenone and renal oxidative stress Ended
  2023-508266-15-00 Phase III 1 country Universitaetsklinikum Erlangen AöR
• Contribution of PET (positron emission tomography) scans for the preoperative assessment of symptomatic endometriosis lesions: TEP-ENDORUN Ended
  2024-520423-88-00 Phase III 1 country Centre Hospitalier Universitaire De La Reunion
• A Prospective, double-blind, randomized, single centre trial to evaluate the rate of RAAS inhibitor withdrawal or down-titration in non-dial… Ended
  2023-503984-41-00 Phase III 1 country Mario Negri Institute For Pharmacological Research IRCCS
• Obinutuzumab for primary membranous nephropathy: a pilot study in patients with rituximab-resistant or rituximab-dependent nephrotic syndrom… Ended
  2024-515857-93-00 Phase II 1 country Istituto Di Ricerche Farmacologiche Mario Negri
• Rescue Therapy with the Human Anti-CD38 Antibody MOR202 (felzartamab) in Patients with Membranous Nephropathy who Failed Anti-CD20 Target Th… Ended
  2024-513744-28-00 Phase II 1 country Istituto Di Ricerche Farmacologiche Mario Negri
• A Phase 2 Study of Tremelimumab (Day 1 only), Durvalumab (MEDI4736) and Trans-arterial catheter chemoembolization (TACE)in patients with adv… Ended
  2023-510117-26-00 Phase II 1 country University College Dublin

Showing 1–19 of 19 trials